FDA Approves First non-opioid Treatment for Management of Opioid Withdrawal Symptoms in Adults

(May 24, 2018)

Encouraging more widespread innovation and development of safe and effective treatments for opioid use disorder remains top agency priority The U.S. Food and Drug Administration today approved Lucemyra (lofexidine hydrochloride) for the mitigation of... Continue Reading


FDA Approves Aliqopa for Relapsed Follicular Lymphoma

(May 23, 2018)

The U.S. Food and Drug Administration (FDA) granted accelerated approval to Aliqopa® (copanlisib), a novel precision cancer medicine that inhibits phosphatidylinositol 3-kinase (PI3K), for the treatment of adults with relapsed follicular lymphoma who... Continue Reading


FDA Approves Kymriah for Treatment of Relapsed or Refractory Large B-Cell Lymphoma

(May 21, 2018)

On May 1, 2018, the United States Food and Drug Administration (FDA) approved Kymriah (tisagenlecleucel), a CD19-directed genetically modified autologous T-cell immunotherapy, for treatment of adult patients with relapsed or refractory diffuse large B-cell... Continue Reading


FDA Approves Aimovig, A Novel Preventive Treatment for Migraine Headaches

(May 21, 2018)

According to Dr. Jessica Ailani, MD, associate professor of neurology at MedStar’s Georgetown University Hospital and director of the MedStar Georgetown Headache Center, migraines affect over 36 million people in the U.S. yet they are still a poorly... Continue Reading


May Is National Skin Cancer Detection and Prevention Month

(May 18, 2018)

Sun Valley, ID —OMNI Health  (OMNI) announces the launch of skin cancer programs for national skin cancer detection and prevention month. As the month of May brings skin cancer into focus, it’s time to increase public understanding of the disease,... Continue Reading


PARP – Checkpoint Inhibitor Combo Promising in Ovarian Cancer

(May 16, 2018)

CancerConnect News: The combination of a PARP inhibitor and a checkpoint inhibitor appears promising as treatment for patients with ovarian cancer, according to results of a clinical study reported at the 2018 Society for Gynecologic Oncology Annual... Continue Reading


What is a Venous Access Device and What Types are Used for Cancer Patients?

(May 9, 2018)

A venous access device (VAD) is a surgically implanted device that provides long-term access to a major vein. A VAD can be useful for patients undergoing systemic treatment with precision cancer medicines or chemotherapy because it allows for a single... Continue Reading


Smoking and Cancer: Understand the Risk and What You Can Do to Control It

(May 8, 2018)

CancerConnect News: Smoking tobacco cigarettes is responsible for drastically increasing the risk of the developing lung cancer— the number-one cause of cancer-related deaths in the U.S—as well as several other types of cancer (not to mention additional... Continue Reading


FDA Approves Tafinlar® + Mekinist® for Adjuvant Treatment of BRAF V600-mutant Stage III Melanoma

(May 7, 2018)

CancerConnect News: The US Food and Drug Administration (FDA) has approved Tafinlar® (dabrafenib) in combination with Mekinist® (trametinib) for the adjuvant treatment of patients with stage III melanoma with BRAF V600E or V600K mutations, as detected... Continue Reading


U.S. FDA Grants Fast Track Designation to GemRIS™ in Muscle Invasive Bladder Cancer

(May 4, 2018)

CancerConnect News: The United States Food and Drug Administration (FDA) has granted Fast Track designation for GemRIS (TAR-200) for the treatment of patients with organ-confined or locally-advanced Muscle Invasive Bladder Cancer who are unfit for curative... Continue Reading


Lutathera Pepetide Receptor Radionuclide Therapy for NETs

(May 3, 2018)

CancerConnect News: Lutathera (lutetium Lu 177 dotatate) was recently approved for the treatment of neuroendocrine tumors (NETs) that typically occur in the pancreas and gastrointestinal tract. This is the first time a radioactive drug, or radiopharmaceutical,... Continue Reading


Immediate vs Delayed Androgen Deprivation Therapy in Prostate Cancer

(May 1, 2018)

CancerConnect News: There is an ongoing discussion about the optimal timing of using androgen deprivation therapy (ADT) in men with prostate cancer who have relapsed based on a rising prostate-specific antigen (PSA) and in men with early stage prostate... Continue Reading


Next Page »